Literature DB >> 27837392

Recurrent GI Bleeding and Surgery Following the Initial Response to Imatinib Therapy in GIST of the Stomach.

Ihab I El Hajj1, Aref Chehal1, Nagi S El Saghir2.   

Abstract

Entities:  

Keywords:  gastrointestinal bleeding; gastrointestinal stromal tumor; imatinib (tyrosine kinase inhibitor); minimal residual disease; tumor growth

Year:  2005        PMID： 27837392     DOI： 10.1007/s10620-005-1279-8

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  16 in total

1.  Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.

Authors:  H Joensuu; P J Roberts; M Sarlomo-Rikala; L C Andersson; P Tervahartiala; D Tuveson; S Silberman; R Capdeville; S Dimitrijevic; B Druker; G D Demetri
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

Review 2.  Imatinib mesylate--a new oral targeted therapy.

Authors:  David G Savage; Karen H Antman
Journal:  N Engl J Med       Date:  2002-02-28       Impact factor: 91.245

3.  Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

Authors:  R P DeMatteo; J J Lewis; D Leung; S S Mudan; J M Woodruff; M F Brennan
Journal:  Ann Surg       Date:  2000-01       Impact factor: 12.969

4.  Does surgery disseminate or accelerate cancer?

Authors:  M Baum
Journal:  Lancet       Date:  1996-01-27       Impact factor: 79.321

Review 5.  Management of malignant gastrointestinal stromal tumours.

Authors:  Heikki Joensuu; Christopher Fletcher; Sasa Dimitrijevic; Sandra Silberman; Peter Roberts; George Demetri
Journal:  Lancet Oncol       Date:  2002-11       Impact factor: 41.316

Review 6.  Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis.

Authors:  M Miettinen; J Lasota
Journal:  Virchows Arch       Date:  2001-01       Impact factor: 4.064

7.  Treatment with STI571, a tyrosine kinase inhibitor, for gastrointestinal stromal tumor with peritoneal dissemination and multiple liver metastases.

Authors:  Satoshi Yamamoto; Shoji Kubo; Taichi Shuto; Takatsugu Yamamoto; Kazuhiro Hirohashi; Hiromu Tanaka; Shigekazu Takemura; Akishige Kanazawa; Hiroaki Kinoshita
Journal:  J Gastroenterol       Date:  2003       Impact factor: 7.527

8.  Effect of a tyrosine kinase inhibitor STI571 in a patient with hepatic metastases from a duodenal gastrointestinal stromal tumor.

Authors:  Akira Sawaki; Kazuhiko Ohashi; Kenji Yamao; Ken-Ichi Inada; Yasuhiro Shimizu; Akira Matsuura; Tuneya Nakamura; Takashi Suzuki; Kazuo Hara; Kenji Okubo; Ryuzo Ohno
Journal:  J Gastroenterol       Date:  2003       Impact factor: 7.527

9.  Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression.

Authors:  L Holmgren; M S O'Reilly; J Folkman
Journal:  Nat Med       Date:  1995-02       Impact factor: 53.440

10.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

Authors:  George D Demetri; Margaret von Mehren; Charles D Blanke; Annick D Van den Abbeele; Burton Eisenberg; Peter J Roberts; Michael C Heinrich; David A Tuveson; Samuel Singer; Milos Janicek; Jonathan A Fletcher; Stuart G Silverman; Sandra L Silberman; Renaud Capdeville; Beate Kiese; Bin Peng; Sasa Dimitrijevic; Brian J Druker; Christopher Corless; Christopher D M Fletcher; Heikki Joensuu
Journal:  N Engl J Med       Date:  2002-08-15       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.